{"version":"1.0","provider_name":"South Africa Journal","provider_url":"https:\/\/southafricajournal.com","author_name":"sjadmin","author_url":"https:\/\/southafricajournal.com\/author\/sjadmin-s\/","title":"NRx Pharmaceuticals, Lotus Pharmaceuticals e Alvogen Inc. anunciam colabora\u00e7\u00e3o para desenvolver e comercializar o NRX-101 - South Africa Journal","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"nwA0FgVinS\"><a href=\"https:\/\/southafricajournal.com\/nrx-pharmaceuticals-lotus-pharmaceuticals-e-alvogen-inc-anunciam-colaboracao-para-desenvolver-e-comercializar-o-nrx-101\/\">NRx Pharmaceuticals, Lotus Pharmaceuticals e Alvogen Inc. anunciam colabora\u00e7\u00e3o para desenvolver e comercializar o NRX-101<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/southafricajournal.com\/nrx-pharmaceuticals-lotus-pharmaceuticals-e-alvogen-inc-anunciam-colaboracao-para-desenvolver-e-comercializar-o-nrx-101\/embed\/#?secret=nwA0FgVinS\" width=\"600\" height=\"338\" title=\"&#8220;NRx Pharmaceuticals, Lotus Pharmaceuticals e Alvogen Inc. anunciam colabora\u00e7\u00e3o para desenvolver e comercializar o NRX-101&#8221; &#8212; South Africa Journal\" data-secret=\"nwA0FgVinS\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"NRx Pharmaceuticals, Lotus Pharmaceuticals e Alvogen ir\u00e3o colaborar no desenvolvimento e comercializa\u00e7\u00e3o futuros de NRX-101 para tratar a depress\u00e3o bipolar com tend\u00eancia suicida resistente ao tratamento (S-TRBD) para os mercados globais A Lotus Pharmaceuticals vai adquirir os direitos mundiais para o NRX-101 para a S-TRBD, e ser\u00e1 respons\u00e1vel pela comercializa\u00e7\u00e3o do NRX-101 em mercados fora [\u2026]","thumbnail_url":"https:\/\/ci6.googleusercontent.com\/proxy\/mYXKpMrVXcMWctc679n6PEvh3HtjdGMExLXUa0gZDRXscdln7UCj8Tm1ACXowln58vflNHMhio3mOHBw6GNPT-FeELc4_hDAKDbb9aQZWKJ0dQM-2anV1UXYcT5fv-gra-a_68cEnXo=s0-d-e1-ft#https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgyMzk0OSM0MDE1NjI0MzIjNzAwMDEzNTg3"}